8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.644
- G2M_CHECKPOINT+0.639
- MYC_TARGETS_V2+0.523
- MYC_TARGETS_V1+0.518
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.468
- ANGIOGENESIS+0.444
- UNFOLDED_PROTEIN_RESPONSE+0.413
- TGF_BETA_SIGNALING+0.408
- MITOTIC_SPINDLE+0.403
- DNA_REPAIR+0.350
Top 10 suppressed
- KRAS_SIGNALING_DN-0.377
- BILE_ACID_METABOLISM-0.229
- MYOGENESIS-0.228
- XENOBIOTIC_METABOLISM-0.184
- PANCREAS_BETA_CELLS-0.169
- HEME_METABOLISM-0.162
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.116
- P53_PATHWAY-0.113
- ADIPOGENESIS-0.095
- INFLAMMATORY_RESPONSE-0.095
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934813 | — | — | 0.908 |
| 2 | SRR934902 | — | — | 0.901 |
| 3 | SRR934935 | — | — | 0.882 |
| 4 | E1B8B320-25EE-4B2C-B705-AB50C3EF5E29 | — | — | 0.877 |
| 5 | 67719D37-8CC2-42B5-AF44-6D5AC258FDB1 | — | — | 0.875 |
| 6 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.869 |
| 7 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.866 |
| 8 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.864 |
| 9 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.862 |
| 10 | 3DA19761-6FF3-4E8C-AA0F-C04CE2CE7037 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.644 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.639 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.523 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.518 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.468 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.444 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.413 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.408 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.403 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.349 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.328 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.306 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.286 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.261 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.228 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.215 | Inavolisib | — uncovered |
| APOPTOSIS | 0.188 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.172 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.162 | Inavolisib | — uncovered |